A REVIEW ANALYSIS ON CREATION AND CONFIRMATION OF STABILITY SPECIFYING TECHNIQUES FOR DRUG RELATED TO RESPIRATION ILLNESSES

Kandiboti Lavanya
Research Scholar
Department of Pharmacy
Sunrise University, Alwar, Rajasthan.
tejharsha24@gmail.com

Dr. Priya Jain
Research Guide
Department of Pharmacy
Sunrise University, Alwar, Rajasthan.

ABSTRACT

The review based on the creation and validation of stability indicating techniques for medications treating respiratory illnesses is the subject of the present study. The development of analytical techniques for the numerous marketable drug classes requires a thorough literature review. More straightforward and precise analytical procedures were required for the medications that had limited analytical options. The goal of the study proposal under consideration was to create and test fresh analytical techniques. Delivering straightforward, accurate, precise, focused, repeatable, reliable, cost-effective, and highly sensitive procedures is the main goal of this work.

Keywords- *Medications, respiratory disorders, reliable.*

INTRODUCTION

Pharmaceutical companies focus on quality and quantity to successfully launch medications. For safe medication use, quality and quantity verification were emphasised for drug release. Several analytical methods, from titrimetric to hyphenated, establish quality and quantity in bulk and commercial Pharma goods. From medication development through post-marketing, the pharmaceutical sector uses these analytical methods most. Analytical methods are also utilized to assess dosage form selection and stability throughout manufacture, storage, and environmental conditions. Analytical methods detect contaminants and their quantities in pharmaceutical formulations, which helps build toxicity profiles. Analytical methods also separate API from contaminants produced during medication manufacture and stability studies.

Drug pharmacokinetics may be determined via bodily fluid drug and metabolite analysis. These analytical methods measure physical characteristics of substances/compounds. Volumetric, gravimetric, refractometry, polarimetry, spectroscopy, and chromatography concurrently measure volume, weight, refractive index, polarity index, absorbance or transmittance, peak area, and retention time.

Quality control is included from sample collection to data reporting in any pharmaceutical sector. Pharmaceutical quality control monitors safety, effectiveness, quality, and regulatory compliance with ICH, FDA, MHRA, and CDER. . Pharmaceutical Analysis can best explain how formulation quality and amount affect its effectiveness. Pharmaceutical markets are saturated with more medications and formulations as new dangerous illnesses emerge worldwide. . Pharmaceutical analysis uses different analytical methods to determine quality, quantity, and stability during manufacturing and storage of novel dosage forms. Our study used HPLC and UV Spectrophotometry because drug

analysis is important. These methods are used because of their versatility and consistency. Spectrophotometric procedures, one of the oldest and cheapest, need little practical expertise and strict experimental conditions. HPLC was chosen due to its conventionality, extensive application to roughly 90% of organic substances, and relevance as shown in breakthrough analytical methods like LC-MS, GC-MS, and UPLC These procedures may also be used for medication quality control in labs and pharmaceutical companies.

I. LITERATURE SURVEY

We have chosen a few significant studies that are pertinent to our field of study for this part, and they are as follows:

Prafulla Kumar Sahu et. al. (2017) exhibited several analytical methods for drug analysis quality control, enhancing their robustness with the aid of chemometric application. In this study, many LC methods and hyphenated procedures for various pharmaceuticals were examined. Subsequently, they improved the explanation of initial screening and design optimization using several QbD components. Also, a short explanation of the Lean Six Sigma concept, which serves as a quality indicator for chromatographical results, was provided.

SushantBhimraoJadhav et al. (2016) RP UPLC in combination with TOF/MS was used to find contaminants in Omeprazole that are not listed in the pharmacopoeia using a two-level factorial design. They used a stationary phase made of an Acquaity BEH RP 18 column. The deteriorated impurities are located and further verified with the aid of a design specialist.

Christine Bousses et al. (2015) a method for dextromethorphan was creatively devised by combining QbD with analytical green chemistry techniques using UHPLC. Regulatory requirements strongly encourage the use of QBD, however this technique hasn't yet been widely accepted in the creation of analytical methods. The ultimate objective of this effort was to strengthen the quality methods used by regulatory organizations.

Blessy M. et al. (2014) current developments regarding the effectiveness of forced degradation experiments were presented. Also emphasized were the significance of performing forced deterioration experiments and making methodologies for conducting stress research accessible. Clarifying the structure of the degradation products requires a thorough understanding of the drug substance's degradation process and degradation products. Forced degradation studies may provide this information since the chemical behavior of the molecule plays an increasing role in formulation development.

Aneesh T. P. et al. (2012) explained the significance of forced degradation experiments for a thorough knowledge of the stability of bulk and pharmaceutical products (DP). These investigations are very helpful in instances when there is minimal knowledge about possible degradants since they provide details on the routes of degradation and the degradation products that are anticipated to occur during storage. They aid in tasks like formulation development, manufacturing, and packaging for meeting regulatory requirements, which call for understanding of chemical behavior.

Mastanamma SK et al. (2018) For the

simultaneous measurement of sofosbuvir and ledipasvir in bulk and tablet dosage form, a straightforward, precise, economical, and reverse phase liquid chromatographic approach has been established. Ledipasvir and Sofosbuvir may be effectively separated from their degradation products using this approach. Using a Luna C18 column of 250 mm x 4.6 mm and 5 mm, separation was accomplished at a wavelength of 227 nm using an isocratic elution mode and a mobile phase made up of acetonitrile and triethylamine buffer (pH-2.5) at a ratio of 50:50. Sofosbuvir and Ledipasvir were shown to have retention times of 4.905 and 2.751 min, respectively. The aforementioned medication combination was exposed to stress environments that included thermal, photolytic, acidic, base, and neutral hydrolysis. As a result, the suggested analytical approach was used to assess stressed samples. For Sofosbuvir and Ledipasvir, quantitation was accomplished using UV detection at 227 nm based on peak area with a linear calibration curve at concentration ranges of 1–15 mg/mL and 0.25–3.75 mg/mL, respectively. With Sofosbuvir and Ledipasvir, the LODs were 0.25 and 0.0625, respectively. The LOQs were discovered to be 0.05 for Ledipasvir and 0.5 for Sofosbuvir. As there were no peaks of degrades or excipient that interfered with the suggested approach, it was determined to be accurate and forced degradation. Due to its ease of use, speed, and incredible precision and accuracy, the suggested approach was thus ideal for use in quality-control labs for quantitative analysis of both the medications taken alone and in combination dose form.

Sunder B. S. et al. (2018) For the measurement of ledipasvir and sofosbuvir in plasma, a unique, sensitive, and accurate high-performance liquid chromatographic technique with ultraviolet/visible light detection (HPLC-UV/VIS) was developed and validated. The analytes were extracted using the liquid extraction technique using a chromatograph with an Oyster BDS RP-C18 column and a mobile phase made up of acetonitrile and buffer solution, methanol, and acetonitrile in the ratio of 200:600:200 (V/V). UV detection at a wavelength of 238 nm and a flow rate of 1.0 mL/min were used. Ledipasvir and Sofosbuvir had retention times of 4.61 and 9.09 minutes, respectively. Linearity was discovered to be between 250 and 2000 ng/mL for ledipasvir and Sofosbuvir for each medication, respectively. Precision has a coefficient of variation of less than 2% both within and between days. According to USFDA requirements, the technique was verified, and the findings fulfilled the standards for acceptability for selectivity, sensitivity, linearity, precision, accuracy, recovery stability of the solution, stability of the solution in plasma, and dilution integrity.

Vikas PM et al. (2016) created an RP-HPLC technique for the measurement of sofosbuvir in bulk that is easy, accurate, precise, repeatable, and specific. SFS was effectively separated using an isocratic method on a Hisil C18 (4.6 x 250mm, 5 m) Waters or similar using a phosphate buffer (4.0 pH): methanol (50:50% V/V) at a flow rate of 0.8 mL/min, with a retention time of 1.01 minutes. The response was discovered to be linear in the drug concentration range of 5 g/mL to 30 g/mL after the method's validation. It was discovered that the slope, intercept, and correlation coefficient had the corresponding values of 0.07, 0.4, and

1.000. The intra-day, inter-day, and intra-day, respectively, RSD values for system precision and method precision were determined to be 0.19%, 0.21%, and 0.20%, 0.23%.

A LR et al. (2019) For the simultaneous measurement of Sofosbuvir and Velpatasvir in tablet dose form, a straightforward, accurate, and exact RP-HPLC approach was established. The m) column was used to perform the chromatogram. At a flow rate of 1 mL/min, mobile phase comprising the buffer Discovery C18 (250 x 4.6 mm, 5 0.1% OPA: acetonitrile taken in the ratio 50:50 V/V) was passed across the column. 30°C was kept as the temperature. The 240 nm optimized wavelength was chosen. The technique was linear for the sofosbuvir concentration range of 100-600 g/mL and the velpatasvir concentration range of 25-150 g/mL. Sofosbuvir and Velpatasvir were shown to have retention durations of 2.473 and 3.316 minutes, respectively. Sofosbuvir and Velpatasvir were found to have %RSD values for system precision, repeatability, and intermediate precision of 0.2 and 0.3, respectively. With Sofosbuvir and Velpatasvir, the recovery percentages were 99.32% and 100.43%, respectively. LOD and LOQ values from Sofosbuvir and Velpatasvir regression equations were 0.44, 1.32 and 0.33, 1.01, respectively. For the regular quantitative analysis of pharmaceutical formulations including Sofosbuvir and Velpatasvir in combination tablet dosage form, the approach was validated and effectively used.

The development of analytical techniques for the numerous marketable drug classes requires a thorough literature review. More straightforward and precise analytical procedures were required for the medications that had limited analytical options. The goal of the current study was to create and test novel analytical techniques. Delivering straightforward, accurate, precise, targeted, repeatable, reliable, cost-effective, and highly sensitive procedures is the main goal of this work.

II. PROPOSED METHODOLOGY

As part of the research approach, the steps below are used.

Figure 1: Project Implementation Methodology



VI. OBECTIVES OF PROPOSED WORK

The planned work's goals are:

- To create and evaluate HPLC techniques that are compatible with MS that can be used to analyze the medication of choice.
- To create and test forced degradation stability indicators for specific medications.
- To provide procedures that is easy to use, accurate, precise, targeted, repeatable, inexpensive, and extremely sensitive.
- To quantitatively calibrate the developed methodologies.

VII. CONCLUSION

It has been determined that thorough

literature reviews are crucial for the development of analytical techniques for the many kinds of medications that are sold today. More straightforward and precise analytical procedures were required for the medications that had limited analytical options. The goal of the current study was to create and test novel analytical techniques. Delivering straightforward, accurate, precise, targeted, repeatable, reliable, cost-effective, and highly sensitive procedures is the main goal of this work.

REFERENCES

1. *S. R. Crouch, D. A. Skoog, F. J. Holler FJ, D. M. West, "Fundamentals of analytical chemistry," Thomson Brooks, California, USA, 8th Edition, Page No. 1-3, 2007.*
2. *G. D. Christian, "Analytical chemistry," Wiley India, New Delhi, India, 4th Edition, Page No. 1 -2,2007.*
3. *B. K. Sharma, "Instrumental methods of chemical analysis," Krishna Prakashan Media (P) Ltd., New Delhi, India, 22nd Edition, Page No. S3-S8, 2007.*
4. *J. Mendham, R. C. Denney, J. D. Barnes, M. J. K. Thomson, "Vogel's text book of quantitative chemical analysis," Dorlin g Kindersley (India) Pvt. Ltd., New Delhi, India, 6th Edition, Page No. 31 -36,2006.*
5. *P. D. Sethi, "HPLC Quantitative analysis of pharmaceutical formulations," CBS Publishers and Distributors, New Delhi, India, 1st Edition, Page No. 3-59, 2001.*
6. *D. A. Skoog, F. J. Holler, S. R. Crouch, "Instrumental analysis," Brooks Cengage Learning, California, USA, Page No. 13-15, 2007.*
7. *W. E. Pickering, "Modern analytical chemistry," Marcel Dekker Inc., New York, USA, 2nd Edition, Page No. 1 -3, 1975.*
A. *H. Beckett, J. B. Stenlake,"Practical pharmaceutical chemistry Vol. II," Cambridge University Press, Cambridge, England, 4th Edition, Page No. 275-279,1988.*
8. *M. Willard, S. Dean, "Instrumental methods of analysis," CBS Publications. New Delhi, India, 6th Edition, Page No. 118 -139,1997.*
9. *D. G. Watson, Pharmaceutical analysis, a text book for pharmacy students and pharmaceutical chemists. Churchill Livingstone, London, UK, 2nd Edition, Page No. 87-92,2005.*
10. *G. Chatwal, S. K. Anand,"Instrumental methods of chemical analysis," S Chand Publications, New Delhi, India, 5th Edition, Page No. 1.1-1.8, 2002.*
11. *G. W. Ewing GW, P. W. Raymond, "Analytical instrumentation," Marcel Dekker Inc., New York, USA, 2nd Edition, Page No. 1123 - 1140, 1997.*
12. *K. A. Connors, G. L. Amidon, V. J. Stella, "Chemical stability of pharmaceuticals," John Wiley & Sons Ltd., New Jersey, USA, 1st Edition, Page No. 248-263, 1986.*
13. *R. Brown, M. Caphart, P. Faustino, R. Frankewich, J. Gibbs, E. Leutzinger, G. Lunn, Y. Chiu, E. Sheinin,"Analytical procedures and method validation: highlights of FDA's draft guidance," Chromatography Online., Vol. 19, Issue 1, Page No. 74-79,2001.*
14. *J. Ermer, "Validation in pharmaceutical analysis Part I: an integrated approach," Journal of Pharmaceutical and Biomedical Analysis.,Vol. 24, Issue 5-6, Page No. 755-767,2001.*
15. *N. Agrawal, J. Esteve-Romero, N. P. Dubey, D. Abhilasha, D. Bose, J. Peris-Vicente, S. Carda-Broch, "Determination of Paroxetine in pharmaceutical preparations using HPLC with electrochemical detection," The Open Analytical Chemistry Journal., Vol. 7, Page No. 1- 5,2013.*
A. *Suman, "New HPLC method development for analysis of Paroxetine in plasma and formulation," South Pacific Journal of Technology and Science.,Vol. 1, Issue 1, Page No. 37-52, 2013.*
16. *M. L. Surekha, G. Kumaraswamy, G. L. Ashwini, "Validated RP-HPLC method for the estimation of Paroxetine hydrochloride in bulk and tablet dosage form," Journal of Pharmacy Research., Vol. 5, Issue 3, Page No. 1768-1770, 2012.*
17. *P. K.Sahu, R. N. Rao, T.Cecchi, S. Swain, C. S.Patro, J. Panda, "An Overview of Experimental Designs in HPLC Method Development and Validation," Journal of Pharmaceutical and Biomedical Analysis, Vol. 17, Page No. 51 -62, 2017.*
18. *H. Alexander, I. Molnar, "Using an innovative Quality-by-design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations," Journal of Pharmaceutical and Biomedical Analysis., Vol. 78 -79, Page No. 65-74,*

2013.

19. S. B.Jadhav, C.K.Kumar, R.Bandichhor, P.N.Bhosale, "Development of RP-UPLC-TOF/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities," Journal of Pharmaceutical and Biomedical Analysis., Vol. 116, Page No. 370-379, 2016.

***III.** S. Janardhan, R.Manavalan, K.Valliappan, "Chemometric technique for the optimization of chromatographic system: Simultaneous HPLC determination of Rosuvastatin, Telmisartan, Ezetimibine and Atorvastatin used in combined cardiovascular therapy," Arabian Journal of Chemistry., Vol. 9, Page No. S1378-S1387, 2016.*

20. C.Bousses, L.Ferey, E.Vedrines, K.Gaudin, "Using an innovative combination of quality-by –design and green analytical chemistry approaches for the development of a stability indicating UHPLC method in pharmaceutical products," Journal of Pharmaceutical and Biomedical Analysis., Vol. 115, Page No. 114-122, 2015.

21. T. P. Aneesh, A. Rajasekaran,"Forced Degradation Studies - A Tool for Determination of Stability in Pharmaceutical Dosage Forms," International Journal of Biological & Pharmaceutical Research., Vol. 3, Issue 5, Page No. 699-702, 2012.

22. M. Blessy, D. Ruchi, N. Prajesh, Y. K. Agrawal, "Development of forced degradation and stability indicating studies of drugs—A review," Journal of Pharmaceutical Analysis., Vol. 4, Issue 3, Page No. 159-165, 2014.

I. Bhattacharyya, S.Basak, A. Maity, S. K Ghosh, "Isolation and Characterization of Acid and Base Degradation Products in Atenolol and Hydrochlorothiazide and A Validated Selective Stability-Indicating HPLC–UV Method for Their Quantification," International Journal of Advances in Pharmaceutical Analysis., Vol. 5, Issue 2, Page No. 36 -41, 2015.

23. E. BellurAtici, B. Karlıga, "Identification, Synthesis and Characterization of Process Related Impurities of Benidipine Hydrochloride, Stress-Testing/Stability Studies and HPLC/UPLC Method Validations," Journal of Pharmaceutical Analysis., Page No. 256-268, 2015.

24. T. K.Laha, S. Sen, "A Validated Stability Indicating Reversed Phase High Performance Liquid Chromatographic Method of Leflunomide and Characterization of Its Degradation Products through Retro-Synthesis," Journal of Applied Pharmaceutical Science., Vol. 7, Issue 5, Page No. 12-17, 2017.

25. R. N. Rao, C. G. Naidu, K. G. Prasad, B. Santhakumar, S.Saida, "Development and Validation of A Stability Indicating Assay of Doxofylline by RPHPLC: ESI-MS/MS, 1H And 13C NMR Spectroscopic Characterization of Degradation Products and Process Related Impurities," Journal of Pharmaceutical and Biomedical Analysis., Vol. 78-79, Page No. 92-99, 2013.

26. D. Kaushik, G. Bansal, "Four New Degradation Products of Doxorubicin: An Application of Forced Degradation Study and Hyphenated Chromatographic Techniques," Journal of Pharmaceutical Analysis., Vol. 5, Page No. 285-295, 2015.

27. R. N. Rao, K. Ramakrishna, B.Sravan, K.Santhakumar, "RP-HPLC Separation and ESI-MS, 1H, and 13C NMR Characterization of Forced Degradants Including Process Related Impurities of Carisbamate: Method Development and Validation," Journal of Pharmaceutical and Biomedical Analysis., Vol. 77, Page No. 49-54, 2013.

28. Y. Yang, X. Zhu, F. Zhang,W. Li, Y. Wu, L. Ding, "Stability-Indicating HPLC Method Development and Structural Elucidation of Novel Degradation Products in Posaconazole Injection by LC–TOF/MS, LC–MS/MS and NMR," Journal of Pharmaceutical and Biomedical Analysis., Vol. 5, Page No. 165-177, 2016.

29. S. S. Abbas , M. R. Elghobashy, R. F. Shokry, L. I. Bebawy, "Stability Indicating HPLC and Spectrophotometric Methods for the Determination of Bupropion Hydrochloride in The Presence of its Alkaline Degradates and Related Impurity," Bulletin of Faculty of Pharmacy, Cairo University., Vol. 50, Page No. 49-59, 2012.

30. N. R.Ramisetti, R.Kuntamukkala, S.Lakshetti, P.Sripadi, "Identification and Characterization of Stress Degradants of Lacosamide by LC– MS and ESI-Q-TOF-MS/MS: Development and Validation of Astability Indicating RPHPLC," Journal of Pharmaceutical and Biomedical Analysis., Vol. 95, Page No. 256-264, 2014.

31. Y. Qingmei, W. Ding, F. Rinaldi, Y. Huang, S. A. Miller, M.Bolgar, "Structural

Characterization of Low Level Degradants in Aztreonam Injection and an Innovative Approach to Aid HPLC Method Validation," Journal of Pharmaceutical and Biomedical Analysis., Vol. 124, Page No. 358-364, 2016.

32. M.Bakshi, T.Ojha, S. Singh, "Validated Specific HPLC Methods for Determination of Prazosin, Terazosin and Doxazosin in The Presence of Degradation Products Formed Under ICH-Recommended Stress Conditions," Journal of Pharmaceutical and Biomedical Analysis., Vol. 34, Page No. 19-26, 2004.

33. D. P. Sonune DP, M. M. Kumar, "Isolation, Characterization of Degradation Products of Sitagliptin and Development of Validated Stability-Indicating HPLC Assay Method for Sitagliptin API and Tablets," International Journal of Pharmaceutical Sciences and Research., Vol. 4, Issue 9, Page No. 3494-3503, 2013.

34. S. K. Mastanamma, S. K. Chandini, S. K. Reehana, P. Saidulu,"Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form,"Futur J Pharm Sci., Vol. 4, Issue 2, Page No. 116-123, 2018.

A. P. Rote,J. Alhat, A. A. Kulkarni, "Development and Validation of RPHPLC Method for the Simultaneous Estimation of Ledipasvir and Sofosbuvir in Bulk and Pharmaceutical Dosage Form," International Journal of Pharmaceutical Sciences and Drug Research., Vol. 9, Issue 6, Page No. 291-298, 2017.

B. S. Sunder, A. K. Mittal,"Bio-Analytical Method Development and Validation for Simultaneous Determination of Ledipasvir and Sofosbuvir Drugs in Human Plasma by RP-HPLC Method,"Int J Curr Pharm Res., Vol. 10, Issue 3, Page No. 21-26, 2018.

35. S. Ganapaty, "Development and Validation of a Stability-indicating Method for the Simultaneous Estimation of Sofosbuvir and Ledipasvir by RP-HPLC," Indian J Pharm Sci., Vol. 80, Issue 6, Page No. 1170-1176, 2018.

36. P. M. Vikas,D. V. Kumar, E. Mounika, M. S. Latha, R. Anusha, Y. Sathish, "Development and Validation of New RP-HPLC Method for the Determination of Sofosbuvir in Pure Form," World J. Pharma. Pharma. Sci., Vol. 5, Issue 5, Page No. 775-781, 2016.

37. R. Vejendla, G. Veerabhadram, "Estimation and Validation of Sofosbuvir in Bulk and Tablet Dosage Form by RP-HPLC," International Journal of Pharmacy., Vol. 6, Issue 2, Page No. 121-127, 2016.

38. R. Guguloth,A. Madhukar, N. Kannappan, A. Ravinder, K. Sravanthi, "Analytical Method Development and Validation of Sofosbuvir tablets by RP-HPLC," Journal of Pharma Research., Vol. 5, Issue 7, Page No. 161-163, 2016.

39. M. R. Rezk,E. B. Basalious, M. E. Amin, "Novel and sensitive UPLCMS/MS method for quantification of Sofosbuvir in human plasma: application to a bioequivalence study," Biomedical Chromatography., Vol. 30, Issue 9, Page No. 1354-1362, 2016.

40. D. Bhatt, P. Thatavarthi,B.Rajkamal, "A quantitative RP-HPLC method development and validation for Sofosbuvir in bulk and tablet dosage form," International Journal of Pharmacy and Analytical Research., Vol. 7, Issue 2, Page No. 165-171, 2018.

J. Singh,S. Bhatt, R. Prasad,"HPLC Method for Estimation of Drug Release of Sofosbuvir on Pharmaceutical Formulation," International Journal of Pharmaceutical Sciences and Research., Vol. 10, Issue 1, Page No. 367-372, 2019.

A. S. Eldin,S. M.Azab, A. Shalaby, M. El-maamly, "The Development of a New Validated HPLC and Spectrophotometric Methods for the Simultaneous Determination of Daclatasvir and Sofosbuvir: Antiviral Drugs," Journal of Pharmacy and Pharmacology Research., Vol. 1, Issue 1, Page No. 28-42, 2017.

A. LR, A. Pallavi, "Method Development and Validation of Stability Indicating RPHPLC Method for Simultaneous Estimation of Sofosbuvir and Velpatasvir in Tablet Dosage Form," Pharmaceutical Sciences & Analytical Research Journal., Vol. 2, Issue 1, Page No. 1-8, 2019.

41. N. Pal,S. R.Avanapu,"New Method Development and Validation for the Determination of Ledipasvir in Bulk Drug Form by Using Reverse Phase HPLC Technique," World Journal of Pharmacy and Pharmaceutical Sciences.,Vol. 5, Issue 8, Page No. 1312 -1321, 2016.

42. M. SK, V. Jupally, "A Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Determination of Lamivudine and Zidovudine in Combined Dosage Form," Indo American Journal of Pharmaceutical Research., Vol. 4, Issue 3, Page No. 1289-1297, 2014.